Wei Wang
Directeur/Bestuurslid bij MingMed Biotechnology Co., Ltd.
Profiel
Wei Wang is currently a Member-Supervisory Board at MingMed Biotechnology Co., Ltd.
He obtained an MBA from The University of Hull in 2003.
Actieve functies van Wei Wang
| Bedrijven | Functie | Begin |
|---|---|---|
MingMed Biotechnology Co., Ltd.
 MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Directeur/Bestuurslid | 24-06-2022 |
Opleiding van Wei Wang
| The University of Hull | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Health Technology |
